Clinical Trials Logo

Depressive Disorder, Major clinical trials

View clinical trials related to Depressive Disorder, Major.

Filter by:

NCT ID: NCT02843373 Completed - Depression Clinical Trials

Brain-Based Biomarkers in Response to TMS in MDD

Start date: March 2016
Phase:
Study type: Observational

The overarching goal of this research program is to elucidate causal and directional neural network- level abnormalities in depression, and how they are modulated by an individually-tailored, circuit-directed intervention. By using concurrent TMS and EEG, the investigators can overcome a major limitation of EEG - the inability to demonstrate causality. Here, we plan to recruit patients with medication-resistant depression undergoing rTMS treatment. At multiple time points, we will perform TMS-EEG to investigate the excitability and connectivity profiles of brain networks and how they are modulated during treatment. This study aims to provide objective brain network measures that can predict and track clinical response to TMS treatment. Findings from this study will be utilized to develop a novel, personalized treatment protocol based on individual brain networks.

NCT ID: NCT02839798 Terminated - Bipolar Disorder Clinical Trials

NeoSync TMS Treatment for Bipolar I Depression

NESTTBID
Start date: May 2016
Phase: Phase 2
Study type: Interventional

This study is designed to evaluate the safety and preliminary efficacy of synchronized transcranial magnetic stimulation (sTMS) using the NeoSync EEG Synchronized TMS device (NEST) in subjects with Bipolar Disorder type I in a Major Depressive Episode. This is an open label study in which subjects will receive treatment 5 days per week for 6 weeks.

NCT ID: NCT02838043 Completed - Depression Clinical Trials

The Efficacy, Safety, and Tolerability of Probiotics on the Mood and Cognition of Depressed Patients

Start date: August 2016
Phase: Phase 3
Study type: Interventional

This study will be an 8-week open-label pilot study examining subjective and objective changes in mood, anxiety, cognition, and sleep before and after the introduction of a probiotic supplement containing Lactobacillus helveticus and Bifidobacterium longum in 10 treatment-naïve participants diagnosed with major depressive disorder (MDD). In order to examine the full composition of the micro biome, the investigators will also be collecting and analyzing fecal samples as well as blood samples to examine changes in plasma levels of inflammatory markers, 5-HT, and tryptophan in order to look at possible underlying mechanisms of any changes seen.

NCT ID: NCT02837887 Completed - Clinical trials for Major Depressive Disorder

Computerized Cognitive Behavior Therapy in Treating Depression in Patients With Cancer

Start date: July 15, 2016
Phase: N/A
Study type: Interventional

This randomized clinical trial studies how well a computerized cognitive behavior therapy program works in treating depression in patients with cancer. The cognitive behavior therapy program uses a series of internet-delivered sessions intended to help patients identify and change problematic patterns of thinking and behavior that maintain depression.

NCT ID: NCT02830399 Completed - Clinical trials for Major Depressive Disorder

Clinical Trial on Efficacy of rTMS to Improve ECT in Treatment-Resistant Depression

STIMAGNECT
Start date: July 15, 2016
Phase: N/A
Study type: Interventional

It's a prospective, multicentric, randomized, controlled study concerning 56 patients with treatment-resistant depression (TRD). The main objective of this study was to evaluate the efficacy of priming repeated Transcranial Magnetic Stimulation (rTMS) sessions before Electroconvulsive therapy (ECT) for treatment of TRD patients. The primary outcome will be the depressive symptoms intensity measured with the Hamilton Rating Scale For Depression (HAMD-21 items) after 5 ECT. The secondary outcome is to evaluate the safety and most particularly the cognitive effects of this association.

NCT ID: NCT02829671 Completed - Clinical trials for Major Depressive Disorders

Loneliness and Occurrence of Suicide Attempts and Suicidal Ideas

SOLSTIS
Start date: October 11, 2016
Phase: N/A
Study type: Interventional

Suicide is a major health problem that causes annually a million death worldwide. Loneliness is known to be associated with suicidal ideation in minors and to be related with suicidal risk in elderly people. However little is known about this association in a middle-aged population. Loneliness is a modifiable factor with suitable psychotherapeutic measures, it is essential to improve the scientific and medical knowledge about the link between this feeling and suicide risk in a population of depressed patients in middle age. The main objective is the study of the relationship between loneliness and the occurrence of suicidal behavior (SB) in major depressed adult population over 12 months. The secondary objectives are: - Identification of risk factors (clinical, neuropsychological and biological) of the occurrence of SB within a clinical population and their interaction; - Identification of predictive factors (clinical, neuropsychological, biological) therapeutic response to antidepressant in the context of depression.

NCT ID: NCT02824081 Recruiting - Clinical trials for Major Depressive Episode

Neuroinflammation, Serotonin, Impulsivity and Suicide

NISIS
Start date: November 2015
Phase: N/A
Study type: Interventional

Suicide is a major health problem that causes annually a million death worlwide. In the stress-vulnerability model, suicidal behavior (SB) results from the interaction between an individual's predisposition (personality, family history of SB…) and stressful conditions (early life adversity). Studies show that suicide ideations could favour inflammation and that depression is associated with an elevated inflammation. Recent evidences also suggest that inflammatory mediators play a critical role in SB. The aim of the study is to evaluate the inflammatory markers rate on depressed patients with or without personal history of SB. In the second part of the study, the relations between the rates of inflammatory markers and characteristics of SB, impulsivity, psychological pain, childhood abuse and gene expression of 5HT2B receptor will be investigated.

NCT ID: NCT02816138 Completed - Clinical trials for Major Depressive Disorder

Depressed Mood Improvement Through Nicotine Dosing (Depressed MIND Study)

Start date: October 2016
Phase: Phase 4
Study type: Interventional

Late-life depression is characterized by both affective (mood) symptoms and cognitive deficits. There is currently no intervention that may provide consistent benefits to both mood and cognitive performance. Agonist activity at the nicotinic acetylcholine receptors via transdermal nicotine patches may provide benefit to both mood and cognition, working through nicotine's effects on brain neural networks, specifically the cognitive control network and default mode network. In this initial pilot project, the investigators will test this hypotheses in 15 nonsmoking depressed elders with subjective cognitive impairment. Following baseline neuroimaging and cognitive testing, participants will receive 12 weeks of open-label transdermal nicotine. Afterwards, participants will repeat neuroimaging and cognitive assessments.

NCT ID: NCT02815813 Completed - Obesity Clinical Trials

Lifestyle Intervention for Young Adults With Serious Mental Illness

Start date: July 3, 2017
Phase: N/A
Study type: Interventional

This is a four year project evaluating the effectiveness of a group-based lifestyle intervention (PeerFIT) supported by mobile health (mHealth) technology and social media compared to Basic Education in fitness and nutrition supported by a wearable Activity Tracking device (BEAT) in achieving clinically significant improvements in weight loss and cardiorespiratory fitness in young adults with serious mental illness (SMI).

NCT ID: NCT02811198 Recruiting - Clinical trials for Major Depressive Disorder

Pain, Reward, Attention and Neurocircuitry: Biomarkers of Suicidality

Start date: January 2017
Phase:
Study type: Observational

The ultimate aim of this study is to identify a biomarker of suicide risk in MDD by measuring the "hedonic spectrum" (pain and reward responsivity), attention and its associated brain structures using brain scans (fMRI and DTI), as well as the stability of markers over time.